TY - JOUR
T1 - The effect of lavender aroma for anxiety disorder
T2 - a study protocol for a multicenter, double-masked, randomized, placebo-controlled clinical trial
AU - Amitani, Haruka
AU - Nishi, Ryusei
AU - Sagiyama, Kenichiro
AU - Fukumoto, Takamasa
AU - Funakoshi, Kouta
AU - Takayanagi, Naomi
AU - Watanabe, Hiroko
AU - Hirose, Masayuki
AU - Tagawa, Koshiro
AU - Ota, Keiko
AU - Ito, Yoichi M.
AU - Asakawa, Akihiro
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Background: Anxiety disorder is the most prevalent psychiatric disorder. Benzodiazepines, which are often used for anxiety in patients with anxiety disorder, have various side effects. Lavender, one of the most commonly used essential oils in aromatherapy, has the potential to reduce benzodiazepine use for anxiety disorders. Methods: This study is a multicenter, double-masked, randomized, placebo-controlled clinical trial. The study will recruit patients aged 20–59 years old with generalized anxiety disorder and panic disorder among anxiety disorders. The bottle containing the test solution (lavender aroma essential oil or distilled water) will be given to the patients. Patients will carry the bottles with them in their daily life and use the drops on tissue paper when anxious. The primary endpoint is the number of times anxiolytics used in 28 days. Discussion: If the use of benzodiazepines could be reduced by sniffing lavender aroma, which is inexpensive and safe, it would contribute not only to the risks associated with benzodiazepine use but also to the health care economy and could even be added as a standard treatment. Trial registration: University hospital Medical Information Network Clinical Trials Registry (UMIN-CTR), ID: UMIN000034422 Registered 17 January 2019.
AB - Background: Anxiety disorder is the most prevalent psychiatric disorder. Benzodiazepines, which are often used for anxiety in patients with anxiety disorder, have various side effects. Lavender, one of the most commonly used essential oils in aromatherapy, has the potential to reduce benzodiazepine use for anxiety disorders. Methods: This study is a multicenter, double-masked, randomized, placebo-controlled clinical trial. The study will recruit patients aged 20–59 years old with generalized anxiety disorder and panic disorder among anxiety disorders. The bottle containing the test solution (lavender aroma essential oil or distilled water) will be given to the patients. Patients will carry the bottles with them in their daily life and use the drops on tissue paper when anxious. The primary endpoint is the number of times anxiolytics used in 28 days. Discussion: If the use of benzodiazepines could be reduced by sniffing lavender aroma, which is inexpensive and safe, it would contribute not only to the risks associated with benzodiazepine use but also to the health care economy and could even be added as a standard treatment. Trial registration: University hospital Medical Information Network Clinical Trials Registry (UMIN-CTR), ID: UMIN000034422 Registered 17 January 2019.
UR - http://www.scopus.com/inward/record.url?scp=85175867128&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85175867128&partnerID=8YFLogxK
U2 - 10.1186/s12906-023-04231-1
DO - 10.1186/s12906-023-04231-1
M3 - Article
C2 - 37932761
AN - SCOPUS:85175867128
SN - 1472-6882
VL - 23
JO - BMC Complementary Medicine and Therapies
JF - BMC Complementary Medicine and Therapies
IS - 1
M1 - 397
ER -